'In vitro' is Latin for 'in glass,' and that captures the whole idea. An in vitro diagnostic, an IVD, is a test run on a specimen taken out of the body, blood in a tube, a urine sample, a nasal swab, rather than a device used in or on the patient. Pregnancy tests, blood-glucose meters, COVID antigen kits, and the large analyzers in a hospital lab are all IVDs. The category is one of the busiest corners of the medical-device world, and the FDA defines it with care.

The governing definition is in 21 CFR 809.3, the labeling regulation for in vitro diagnostic products. It defines IVDs not as a single object but as a set, reagents, instruments, and systems, unified by what they are for: examining specimens drawn from the human body to learn something about disease or health.

"In vitro diagnostic products are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body."— 21 CFR 809.3, source

Why an IVD is legally a 'device'

The definition closes a crucial loop: it states that these products 'are devices as defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act,' and notes that some may also be biological products under the Public Health Service Act. That single clause does a lot of work. Because an IVD is a device, it is swept into the entire device regulatory framework, the three-class system under section 513, the premarket pathways, and the quality and labeling requirements that apply to devices. An IVD is not a separate regulatory animal; it is a device with a diagnostic job and some extra labeling rules layered on top.

Those extra rules are the rest of 21 CFR Part 809. Because an IVD reports a result that a clinician or a patient will act on, the labeling must convey intended use, performance characteristics, and limitations, so that the test result is interpreted correctly. The regulation also introduces the concept of a 'product class,' all products intended for a particular determination or related group of determinations, which helps organize the sprawling universe of assays into coherent groups.

How IVDs move through classification and clearance

Because IVDs are devices, they ride the same risk-based classification. The FDA's classification database is full of them, each tied to a regulation number, product code, class, and a medical-specialty panel. A real entry: the device type 'Liquid Chromatography, Amphetamine' is listed as Class 2 under regulation number 862.3100, product code DNI, in the Clinical Toxicology specialty. The 862-series regulations are the clinical-chemistry and clinical-toxicology device sections, exactly where many laboratory IVDs are classified.

Class drives pathway here just as it does for any device. A low-risk IVD may be Class I and exempt; a moderate-risk IVD is typically Class II and reaches the market via a 510(k) demonstrating substantial equivalence to a predicate IVD; a high-risk IVD, for instance, a test that drives a critical treatment decision or screens donated blood, can be Class III and require premarket approval. A genuinely novel IVD with no predicate can use the De Novo pathway to establish a new classification. So the diagnostic context does not change the machinery; it just populates it with assays instead of, say, surgical instruments.

One distinction is worth flagging for readers parsing test labels. Some IVDs are sold as finished products and carry FDA clearance or approval; others are 'laboratory-developed tests' designed and run within a single lab, a category with its own evolving regulatory treatment. And separately, the place where an IVD is performed is governed by CLIA, the Clinical Laboratory Improvement Amendments, which sets requirements for the labs that run the tests, distinct from the FDA's authority over the test product itself. The clean mental model is two questions: what is the test (an FDA-regulated device under Part 809) and where is it run (a CLIA-regulated laboratory). The definition in 21 CFR 809.3 answers the first, and answers it broadly enough to cover everything from a pocket glucose strip to a room-sized analyzer.

Why the labeling rules in Part 809 carry extra weight

For most medical devices, labeling tells a user how to operate the device safely. For an IVD, the labeling has a heavier job: it has to make a numeric or qualitative result interpretable. A blood-glucose reading or a positive antigen line is only as useful as the user's understanding of what the test measures, how accurate it is, and where it can mislead. That is why 21 CFR Part 809 layers IVD-specific content onto the general device labeling rules, intended use, the methodology, performance characteristics, and the limitations of the procedure, so that the person acting on the result has the context to act correctly. The definition in 809.3 sits at the front of that part precisely because everything downstream, the labeling obligations, the product-class grouping, flows from what counts as an IVD in the first place.

The breadth of the definition is also deliberate. By naming reagents, instruments, and systems, the regulation reaches a single antibody reagent, the analyzer that reads it, and the integrated platform that combines collection, preparation, and examination, treating all of them as in vitro diagnostic products. It also explicitly anticipates overlap with biologics, noting that an IVD 'may also be biological products subject to section 351 of the Public Health Service Act,' which is how certain blood-screening and other tests come under additional authority. The takeaway for a reader is that 'IVD' is not a narrow product label but a regulatory category spanning the full chain from specimen to result, anchored in one definition and carried through the device classification system like any other device.